Welcome to our dedicated page for Akoya BioSciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya BioSciences stock.
Akoya BioSciences, Inc. (Nasdaq: AKYA) is a leading life sciences technology company pioneering spatial biology solutions that transform discovery, clinical research, and diagnostics. Akoya is committed to advancing the science of imaging with its comprehensive platforms, including PhenoCycler® and PhenoImager®, that perform deep proteomic profiling and spatial phenotyping. These cutting-edge platforms enable researchers to analyze tissue samples with high precision, providing insights into cellular interactions and disease mechanisms.
In 2024, Akoya announced preliminary unaudited revenue for Q4 2023 between $25.5 million and $26.5 million, marking a significant increase from Q4 2022. For the fiscal year 2023, revenues are expected to reach between $95.6 million and $96.6 million.
Akoya's portfolio includes innovative products like PhenoCode™ Panels, PhenoCycler®, and PhenoImager® HT, which support high-throughput and high-parameter tissue analysis. Notably, the company has recently partnered with Thermo Fisher Scientific to enhance its spatial multiomic workflow by integrating ViewRNA technology.
The company's technology has attracted significant attention in the scientific community, with its systems cited in over 1,300 publications as of March 2024. Akoya has also formed strategic partnerships and collaborations, including with the Queensland Spatial Biology Centre and organizations like BostonGene and NeraCare, enhancing the application of its platforms in various fields of research and clinical diagnostics.
Financially, Akoya aims for substantial revenue growth in 2024 with projections exceeding 20%, supported by its robust balance sheet and strategic initiatives like the new Manufacturing Center of Excellence in Marlborough, MA. This facility is expected to streamline operations, improve supply chain efficiency, and meet the growing demand for spatial biology solutions.
If you're a scientist or software engineer passionate about revolutionizing imaging science, Akoya BioSciences offers an exciting environment for innovation. For more information, contact Akoya at info@akoyabio.com.
Akoya Biosciences (Nasdaq: AKYA) is set to unveil data from its PhenoCycler-Fusion system, which integrates RNA chemistry for whole-slide spatial multiomics at single-cell resolution, at the AGBT conference in Orlando, Florida, from June 6 to 9, 2022. This advancement complements existing spatial proteomics capabilities, enabling comprehensive multiomic analyses on single tissue samples, crucial for understanding disease progression. CEO Brian McKelligon emphasized that this innovation represents a significant advance in spatial biology.
Akoya Biosciences reported a Q1 2022 revenue of $16.9 million, marking a 38% growth year-over-year. Product revenue reached $13.3 million with a 34% increase, while reagent revenue surged 82% to $4.6 million. Gross profit stood at $10.1 million, a 36% increase, with a gross profit margin of 60%. The company raised its FY 2022 revenue guidance to $70-73 million. Key highlights include the launch of the PhenoCycler-Fusion System and the addition of Dr. Ehab El-Gabry as Chief Medical Officer. Akoya has $94 million in cash reserves as of March 31, 2022.
Akoya Biosciences (Nasdaq: AKYA) announces participation in three key investor conferences. The company will present at the Bank of America 2022 Healthcare Conference on May 10, 2022, at 10:40 AM PT, followed by a fireside chat at the UBS Global Life Science Conference on May 23, 2022, at 7:45 AM ET. Additionally, Akoya will have a virtual presentation available on-demand from May 24-26, 2022, during the HC Wainwright Global Investment Conference. Archived webcasts can be accessed on Akoya’s website.
Akoya Biosciences (Nasdaq: AKYA) has appointed Dr. Ehab A. El-Gabry as Chief Medical Officer to enhance its spatial phenotyping solutions in clinical settings. Dr. El-Gabry, a board-certified pathologist with extensive experience, previously led significant advancements at Roche Tissue Diagnostics. His leadership aims to advance Akoya's translational research strategy and improve patient care through innovative diagnostics. CEO Brian McKelligon highlighted Dr. El-Gabry's invaluable expertise during a pivotal time for the company’s growth in the spatial biology sector.
Akoya Biosciences, Inc. (Nasdaq: AKYA) announced the release of its first-quarter 2022 financial results scheduled for May 5, 2022, post-market close. A conference call will follow at 5:00 p.m. ET to discuss these results. Investors can join the call by calling designated numbers or through a live webcast available on the Akoya website. The company focuses on spatial phenotyping solutions for research, impacting disease progression understanding and therapy response.
Akoya Biosciences (Nasdaq: AKYA) is set to present groundbreaking advancements in spatial phenotyping at the AACR 2022 Annual Meeting from April 8 to 13 in New Orleans. The company will unveil the first 100-plex dataset for deep spatial phenotyping at single-cell resolution and showcase a novel universal chemistry aimed at accelerating biomarker validation. The PhenoCycler™-Fusion's high-speed imaging capabilities will facilitate significant insights into tumor-immune biology, while its file compression technology will streamline data management for researchers. These innovations underscore Akoya’s commitment to enhancing cancer research.
Akoya Biosciences, Inc. (Nasdaq: AKYA) reported a solid Q4 2021, with revenues of $16.2 million, a 26% increase from Q4 2020. For FY 2021, it recorded $54.9 million in revenue, marking a 29.5% growth year-over-year. The company saw strong adoption of its spatial biology solutions, growing its installed base to 697 instruments and achieving 278 publications featuring its platforms. Akoya forecasts FY 2022 revenue between $69-71 million. Furthermore, notable partnerships and launches, including the PhenoCycler™-Fusion System, were announced.
Akoya Biosciences (Nasdaq: AKYA) will release its fourth-quarter and full-year 2021 financial results on March 14, 2022, after market close. Management will discuss the results during a conference call at 5:00 p.m. ET. Interested investors can join the call by dialing designated numbers or via a live webcast on the Akoya website. Additionally, Akoya will participate in the Cowen Annual Health Care Conference on March 8, 2022, at 9:50 a.m. ET, where CEO Brian McKelligon and CFO Joe Driscoll will present.
Akoya Biosciences, Inc. (Nasdaq: AKYA), known as The Spatial Biology Company®, will participate virtually in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, at 1 p.m. ET. CEO Brian McKelligon and CFO Joe Driscoll will present during this event, which is exclusive to BTIG clients. Akoya focuses on spatial phenotyping, providing cutting-edge single-cell imaging solutions to enhance research in discovering and treating diseases. More details about Akoya’s solutions can be found at www.akoyabio.com.
Akoya Biosciences announced the appointment of Marilee Moy as Chief People Officer, effective January 20, 2022. With over 30 years of HR experience in the life sciences sector, Moy's leadership is expected to enhance Akoya's human resource strategy during its global growth phase. Her prior roles include senior positions at Talis Biomedical and Counsyl. Akoya focuses on spatial phenotyping, a groundbreaking approach in cell biology, potentially revolutionizing applications in medicine and research.
FAQ
What is the current stock price of Akoya BioSciences (AKYA)?
What is the market cap of Akoya BioSciences (AKYA)?
What does Akoya BioSciences, Inc. do?
What are Akoya's core products?
How did Akoya perform financially in 2023?
Who are some of Akoya's key partners?
What recent achievements has Akoya announced?
How many publications have cited Akoya's technology?
What is Akoya's financial outlook for 2024?
What is the significance of the new Manufacturing Center of Excellence?
Who should consider working at Akoya BioSciences?
How can one contact Akoya BioSciences for more information?
